{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:07:17Z","timestamp":1785366437932,"version":"3.55.0"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Henan Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.molimm.2026.02.011","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:50:33Z","timestamp":1772725833000},"page":"45-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Navigating the frontier of CAR-T cell resistance: From underlying mechanisms to innovative therapeutic solutions"],"prefix":"10.1016","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4909-7661","authenticated-orcid":false,"given":"Fei","family":"Lan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-4681","authenticated-orcid":false,"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.molimm.2026.02.011_bib1","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1021\/acs.molpharmaceut.3c00926","article-title":"Nanoencapsulation of MDM2 Inhibitor RG7388 and Class-I HDAC inhibitor entinostat enhances their therapeutic potential through synergistic antitumor effects and reduction of systemic toxicity","volume":"21","author":"Abed","year":"2024","journal-title":"Mol. Pharm."},{"issue":"10254","key":"10.1016\/j.molimm.2026.02.011_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.molimm.2026.02.011_bib3","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I trial of regional mesothelin-targeted car t-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s12885-022-09489-1","article-title":"Humanized CD19 CAR-T cells in relapsed\/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy","volume":"22","author":"An","year":"2022","journal-title":"BMC Cancer"},{"issue":"625","key":"10.1016\/j.molimm.2026.02.011_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg7565","article-title":"An orthogonal IL-2 and IL-2R\u03b2 system drives persistence and activation of CAR T cells and clearance of bulky lymphoma","volume":"13","author":"Aspuria","year":"2021","journal-title":"Sci. Transl. Med"},{"issue":"23","key":"10.1016\/j.molimm.2026.02.011_bib6","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1158\/1078-0432.CCR-24-1853","article-title":"Preclinical Evaluation of AZD6422, an armored chimeric antigen receptor T Cell Targeting CLDN18.2 in gastric, pancreatic, and esophageal cancers","volume":"30","author":"Barrett","year":"2024","journal-title":"Clin. Cancer Res"},{"issue":"10297","key":"10.1016\/j.molimm.2026.02.011_bib7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.molimm.2026.02.011_bib8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41571-025-00992-5","article-title":"Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma","volume":"22","author":"Bock","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.molimm.2026.02.011_bib9","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat. Med"},{"issue":"5","key":"10.1016\/j.molimm.2026.02.011_bib10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41409-025-02539-9","article-title":"Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma","volume":"60","author":"Canelo-Vilaseca","year":"2025","journal-title":"Bone Marrow Transpl."},{"issue":"11","key":"10.1016\/j.molimm.2026.02.011_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010028","article-title":"ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis","volume":"12","author":"Cao","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.molimm.2026.02.011_bib12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8010","key":"10.1016\/j.molimm.2026.02.011_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","article-title":"FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy","volume":"629","author":"Chan","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100060","article-title":"Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL","volume":"2","author":"Cox","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"12","key":"10.1016\/j.molimm.2026.02.011_bib16","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med"},{"key":"10.1016\/j.molimm.2026.02.011_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2025.09.007","article-title":"Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma","author":"Di Meo","year":"2025","journal-title":"Cancer Cell"},{"issue":"8010","key":"10.1016\/j.molimm.2026.02.011_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","article-title":"FOXO1 is a master regulator of memory programming in CAR T cells","volume":"629","author":"Doan","year":"2024","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.molimm.2026.02.011_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005583","article-title":"Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice","volume":"11","author":"Dong","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.molimm.2026.02.011_bib20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.molimm.2026.02.011_bib21","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1007\/s11010-025-05226-x","article-title":"Effects of FAP+ fibroblasts on cell proliferation migration and immunoregulation of esophageal squamous carcinoma cells through the CXCL12\/CXCR4 axis","volume":"480","author":"Duan","year":"2025","journal-title":"Mol. Cell Biochem"},{"issue":"4","key":"10.1016\/j.molimm.2026.02.011_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140100","article-title":"Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer","volume":"131","author":"Edwards","year":"2021","journal-title":"J. Clin. Invest"},{"issue":"35","key":"10.1016\/j.molimm.2026.02.011_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn9857","article-title":"Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer","volume":"10","author":"Erler","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.molimm.2026.02.011_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109580","article-title":"Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy","volume":"183","author":"Fan","year":"2023","journal-title":"Radio. Oncol."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib25","doi-asserted-by":"crossref","first-page":"8309","DOI":"10.1038\/s41467-024-52503-2","article-title":"Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansion","volume":"15","author":"Fiorenza","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.molimm.2026.02.011_bib26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med"},{"issue":"7709","key":"10.1016\/j.molimm.2026.02.011_bib27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med"},{"key":"10.1016\/j.molimm.2026.02.011_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.25259\/Cytojournal_245_2024","article-title":"Enhanced efficacy of dual chimeric antigen receptor-T cells targeting programmed death-ligand 1 and cancer-associated fibroblasts in colorectal cancer in vitro","volume":"22","author":"Gao","year":"2025","journal-title":"Cytojournal"},{"issue":"9","key":"10.1016\/j.molimm.2026.02.011_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009602","article-title":"Metabolic reprogramming of hypoxic tumor-associated macrophages through CSF-1R targeting favors treatment efficiency in colorectal cancers","volume":"12","author":"Gharzeddine","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.molimm.2026.02.011_bib31","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat. Med"},{"issue":"2","key":"10.1016\/j.molimm.2026.02.011_bib32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood.2023020621","article-title":"CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL","volume":"143","author":"Ghorashian","year":"2024","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.molimm.2026.02.011_bib33","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.molimm.2026.02.011_bib34","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR T(Reg) cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat. Med"},{"issue":"6","key":"10.1016\/j.molimm.2026.02.011_bib35","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","article-title":"Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin. Cancer Res"},{"issue":"9","key":"10.1016\/j.molimm.2026.02.011_bib36","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/s41416-020-1020-6","article-title":"T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting","volume":"123","author":"Hanley","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.molimm.2026.02.011_bib37","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat. Med"},{"issue":"18","key":"10.1016\/j.molimm.2026.02.011_bib38","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-24-2267","article-title":"Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma","volume":"31","author":"Hijazi","year":"2025","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.molimm.2026.02.011_bib39","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ymthe.2021.10.011","article-title":"IL12 integrated into the CAR exodomain converts CD8(+) T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors","volume":"30","author":"Hombach","year":"2022","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010540","article-title":"Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors","volume":"13","author":"Hu","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"8040","key":"10.1016\/j.molimm.2026.02.011_bib41","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41586-024-08071-y","article-title":"Transgelin 2 guards T cell lipid metabolism and antitumour function","volume":"635","author":"Hwang","year":"2024","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.molimm.2026.02.011_bib42","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/2159-8290.CD-21-1586","article-title":"Sequential single-cell transcriptional and protein marker profiling reveals tigit as a marker of CD19 CAR-T cell dysfunction in patients with non-hodgkin lymphoma","volume":"12","author":"Jackson","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.molimm.2026.02.011_bib44","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166028","article-title":"IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models","volume":"133","author":"Jaspers","year":"2023","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib45","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1038\/s41467-025-59818-8","article-title":"Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation","volume":"16","author":"Kimman","year":"2025","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.molimm.2026.02.011_bib46","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1158\/2326-6066.CIR-23-0389","article-title":"Fc\u03b3RIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment","volume":"12","author":"Knorr","year":"2024","journal-title":"Cancer Immunol. Res"},{"issue":"7968","key":"10.1016\/j.molimm.2026.02.011_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-023-06088-3","article-title":"Author Correction: CAR immune cells: design principles, resistance and the next generation","volume":"619","author":"Labanieh","year":"2023","journal-title":"Nature"},{"issue":"15_","key":"10.1016\/j.molimm.2026.02.011_bib48","first-page":"8016","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results","volume":"39","author":"Larry","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.molimm.2026.02.011_bib49","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1158\/2159-8290.CD-22-0964","article-title":"CD19\/CD20 bispecific chimeric antigen receptor (car) in naive\/memory t cells for the treatment of relapsed or refractory non-hodgkin lymphoma","volume":"13","author":"Larson","year":"2023","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.molimm.2026.02.011_bib51","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1158\/0008-5472.CAN-22-0507","article-title":"beta2-Microglobulin Maintains Glioblastoma Stem Cells and Induces M2-like Polarization of Tumor-Associated Macrophages","volume":"82","author":"Li","year":"2022","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib52","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41392-020-00277-6","article-title":"PD-1 abrogates the prolonged persistence of CD8(+) CAR-T cells with 4-1BB co-stimulation","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"issue":"3","key":"10.1016\/j.molimm.2026.02.011_bib53","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41423-023-01120-y","article-title":"SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors","volume":"21","author":"Liang","year":"2024","journal-title":"Cell Mol. Immunol."},{"issue":"ement 1","key":"10.1016\/j.molimm.2026.02.011_bib54","first-page":"26","article-title":"Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study","volume":"136","author":"Lin","year":"2020","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.molimm.2026.02.011_bib55","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1158\/0008-5472.CAN-21-1337","article-title":"ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression","volume":"81","author":"Liu","year":"2021","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.molimm.2026.02.011_bib56","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","article-title":"CD19-specific CAR T Cells that Express a PD-1\/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma","volume":"27","author":"Liu","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.molimm.2026.02.011_bib57","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ajh.26160","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.molimm.2026.02.011_bib58","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/CM9.0000000000003046","article-title":"Targeting metabolism to improve CAR-T cells therapeutic efficacy","volume":"137","author":"Liu","year":"2024","journal-title":"Chin. Med J. (Engl. )"},{"issue":"3","key":"10.1016\/j.molimm.2026.02.011_bib59","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41590-020-00850-9","article-title":"IL-2 regulates tumor-reactive CD8(+) T cell exhaustion by activating the aryl hydrocarbon receptor","volume":"22","author":"Liu","year":"2021","journal-title":"Nat. Immunol."},{"issue":"11","key":"10.1016\/j.molimm.2026.02.011_bib60","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/cac2.12608","article-title":"Tryptophan 2,3-dioxygenase-positive matrix fibroblasts fuel breast cancer lung metastasis via kynurenine-mediated ferroptosis resistance of metastatic cells and T cell dysfunction","volume":"44","author":"Liu","year":"2024","journal-title":"Cancer Commun (Lond)"},{"issue":"11","key":"10.1016\/j.molimm.2026.02.011_bib61","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1038\/s41591-025-03874-6","article-title":"GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial","volume":"31","author":"Locatelli","year":"2025","journal-title":"Nat. Med"},{"issue":"19","key":"10.1016\/j.molimm.2026.02.011_bib62","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.molimm.2026.02.011_bib63","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","article-title":"Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Nat. Med"},{"issue":"10","key":"10.1016\/j.molimm.2026.02.011_bib64","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","article-title":"Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas","volume":"4","author":"Long","year":"2016","journal-title":"Cancer Immunol. Res"},{"issue":"7786","key":"10.1016\/j.molimm.2026.02.011_bib65","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib66","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41420-024-02245-3","article-title":"Systemic tumor regression with synergy therapy: radiotherapy and CAR-T","volume":"10","author":"Ma","year":"2024","journal-title":"Cell Death Discov."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib67","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"issue":"15_","key":"10.1016\/j.molimm.2026.02.011_bib68","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.molimm.2026.02.011_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/nu13124503","article-title":"Arginine and Arginases Modulate Metabolism, Tumor Microenvironment and Prostate Cancer Progression","volume":"13","author":"Matos","year":"2021","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.molimm.2026.02.011_bib70","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib71","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"690","key":"10.1016\/j.molimm.2026.02.011_bib72","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abk1900","article-title":"T(STEM)-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models","volume":"15","author":"Meyran","year":"2023","journal-title":"Sci. Transl. Med"},{"issue":"755","key":"10.1016\/j.molimm.2026.02.011_bib73","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg7123","article-title":"Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities","volume":"16","author":"Mog","year":"2024","journal-title":"Sci. Transl. Med"},{"issue":"69","key":"10.1016\/j.molimm.2026.02.011_bib74","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi4613","article-title":"Transforming growth factor-beta1 in regulatory T cell biology","volume":"7","author":"Moreau","year":"2022","journal-title":"Sci. Immunol."},{"issue":"8011","key":"10.1016\/j.molimm.2026.02.011_bib75","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-024-07352-w","article-title":"PGE(2) inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function","volume":"629","author":"Morotti","year":"2024","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.molimm.2026.02.011_bib76","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.molimm.2026.02.011_bib77","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med"},{"issue":"26","key":"10.1016\/j.molimm.2026.02.011_bib78","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.molimm.2026.02.011_bib79","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat. Med"},{"issue":"9","key":"10.1016\/j.molimm.2026.02.011_bib80","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009552","article-title":"S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling","volume":"12","author":"\u00d6zbay Kurt","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"82","key":"10.1016\/j.molimm.2026.02.011_bib81","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq3016","article-title":"Metabolic challenges and interventions in CAR T cell therapy","volume":"8","author":"Peng","year":"2023","journal-title":"Sci. Immunol."},{"issue":"10","key":"10.1016\/j.molimm.2026.02.011_bib82","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011768","article-title":"Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance","volume":"13","author":"Ponzo","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.molimm.2026.02.011_bib83","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ccell.2025.01.013","article-title":"EZH1\/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models","volume":"43","author":"Porazzi","year":"2025","journal-title":"Cancer Cell"},{"issue":"620","key":"10.1016\/j.molimm.2026.02.011_bib84","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci. Transl. Med"},{"issue":"8","key":"10.1016\/j.molimm.2026.02.011_bib85","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.molimm.2026.02.011_bib86","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002840","article-title":"Tryptophan potentiates CD8(+) T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation","volume":"9","author":"Qin","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.molimm.2026.02.011_bib87","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"18","key":"10.1016\/j.molimm.2026.02.011_bib88","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.molimm.2026.02.011_bib89","article-title":"A CAR enhancer increases the activity and persistence of CAR T cells","author":"Rakhshandehroo","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"20","key":"10.1016\/j.molimm.2026.02.011_bib90","first-page":"2470","article-title":"Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma","volume":"141","author":"Roddie","year":"2023","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.molimm.2026.02.011_bib91","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib92","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","article-title":"CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy","volume":"12","author":"Rodriguez-Garcia","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.molimm.2026.02.011_bib93","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2015.03.005","article-title":"Antagonistic human Fc\u03b3RIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo","volume":"27","author":"Roghanian","year":"2015","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.molimm.2026.02.011_bib94","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.molimm.2026.02.011_bib95","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1158\/2326-6066.CIR-21-1075","article-title":"Targeting Macrophages with CAR T cells delays solid tumor progression and enhances antitumor immunity","volume":"10","author":"S\u00e1nchez-Paulete","year":"2022","journal-title":"Cancer Immunol. Res"},{"issue":"634","key":"10.1016\/j.molimm.2026.02.011_bib96","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm0306","article-title":"A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo","volume":"14","author":"Sandberg","year":"2022","journal-title":"Sci. Transl. Med"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib97","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"10299","key":"10.1016\/j.molimm.2026.02.011_bib98","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.molimm.2026.02.011_bib99","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molimm.2026.02.011_bib100","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fimmu.2021.661357","article-title":"Indoleamine 2,3-Dioxygenase 1 Inhibitor-Loaded Nanosheets Enhance CAR-T cell function in esophageal squamous cell carcinoma","volume":"12","author":"Shao","year":"2021","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.molimm.2026.02.011_bib101","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/s41590-025-02223-6","article-title":"Early methionine availability attenuates T cell exhaustion","volume":"26","author":"Sharma","year":"2025","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molimm.2026.02.011_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1165404","article-title":"IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models","volume":"14","author":"Shi","year":"2023","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib103","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.molimm.2026.02.011_bib104","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.ymthe.2024.05.006","article-title":"GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy","volume":"32","author":"Shi","year":"2024","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.molimm.2026.02.011_bib105","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.21.02143","article-title":"Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy","volume":"40","author":"Shouval","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.molimm.2026.02.011_bib106","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","article-title":"Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell Dysfunction","volume":"10","author":"Singh","year":"2020","journal-title":"Cancer Discov."},{"issue":"6481","key":"10.1016\/j.molimm.2026.02.011_bib107","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"issue":"8047","key":"10.1016\/j.molimm.2026.02.011_bib108","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.molimm.2026.02.011_bib109","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/gutjnl-2021-325808","article-title":"Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases","volume":"72","author":"Sullivan","year":"2023","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.molimm.2026.02.011_bib110","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","article-title":"CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer","volume":"31","author":"Sun","year":"2023","journal-title":"Mol. Ther."},{"issue":"18","key":"10.1016\/j.molimm.2026.02.011_bib111","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.molimm.2026.02.011_bib112","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-beta inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib113","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","article-title":"High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma","volume":"41","author":"Tang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.molimm.2026.02.011_bib114","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00262-024-03909-w","article-title":"CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors","volume":"74","author":"Tian","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.molimm.2026.02.011_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12102381","article-title":"Insights into CSF-1R Expression in the Tumor Microenvironment","volume":"12","author":"Tomassetti","year":"2024","journal-title":"Biomedicines"},{"issue":"7952","key":"10.1016\/j.molimm.2026.02.011_bib116","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.molimm.2026.02.011_bib117","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"issue":"15_","key":"10.1016\/j.molimm.2026.02.011_bib118","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2021.39.15_suppl.8005","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed\/refractory multiple myeloma (R\/R MM): Updated results from CARTITUDE-1","volume":"39","author":"Usmani","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"ement_1","key":"10.1016\/j.molimm.2026.02.011_bib119","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2019-124953","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib120","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13045-021-01120-3","article-title":"Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed\/relapsed after CART19\/20 therapy","volume":"14","author":"Wang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib121","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molimm.2026.02.011_bib122","article-title":"Advances in targeting tumor microenvironment for immunotherapy","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib123","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41408-024-01105-8","article-title":"Bispecific CAR-T cells targeting CD19\/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I\/II trial","volume":"14","author":"Wang","year":"2024","journal-title":"Blood Cancer J."},{"issue":"14","key":"10.1016\/j.molimm.2026.02.011_bib124","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib125","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","article-title":"Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib126","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41392-023-01659-2","article-title":"Characteristics of premanufacture CD8(+)T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"9","key":"10.1016\/j.molimm.2026.02.011_bib127","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-23-3841","article-title":"Mesothelin CAR T Cells Secreting Anti-FAP\/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma","volume":"30","author":"Wehrli","year":"2024","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.molimm.2026.02.011_bib128","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065688","article-title":"CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma","volume":"24","author":"Wittibschlager","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib129","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1038\/s41467-023-42634-3","article-title":"Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1alpha-mediated glycolytic reprogramming","volume":"14","author":"Wu","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib130","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41392-022-00915-1","article-title":"Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies","volume":"7","author":"Yan","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.molimm.2026.02.011_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101053","article-title":"A highly selective PI3K\u03b4 inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon","volume":"57","author":"Yang","year":"2024","journal-title":"Neoplasia"},{"issue":"4","key":"10.1016\/j.molimm.2026.02.011_bib132","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11427-016-5024-7","article-title":"Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells","volume":"59","author":"You","year":"2016","journal-title":"Sci. China Life Sci."},{"issue":"12","key":"10.1016\/j.molimm.2026.02.011_bib133","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41423-023-01093-y","article-title":"The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8(+) T-cell immunity","volume":"20","author":"Yu","year":"2023","journal-title":"Cell Mol. Immunol."},{"issue":"3","key":"10.1016\/j.molimm.2026.02.011_bib134","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cmet.2023.01.010","article-title":"PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy","volume":"35","author":"Zhang","year":"2023","journal-title":"Cell Metab."},{"issue":"7926","key":"10.1016\/j.molimm.2026.02.011_bib135","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.molimm.2026.02.011_bib136","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.7150\/ijbs.100188","article-title":"NUSAP1 is Upregulated by Estrogen to Promote Lung Adenocarcinoma Growth and Serves as a Therapeutic Target","volume":"20","author":"Zhang","year":"2024","journal-title":"Int J. Biol. Sci."},{"issue":"3","key":"10.1016\/j.molimm.2026.02.011_bib137","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00262-021-03009-z","article-title":"Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia","volume":"71","author":"Zhang","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.molimm.2026.02.011_bib138","first-page":"873","article-title":"Exploration of CAR-T cell combination therapy strategies in lymphoma","volume":"43","author":"Zhang","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"2","key":"10.1016\/j.molimm.2026.02.011_bib139","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001150","article-title":"Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib140","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2265703","article-title":"Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor","volume":"12","author":"Zhao","year":"2023","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.molimm.2026.02.011_bib141","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.molimm.2026.02.011_bib142","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/s41423-024-01228-9","article-title":"Specific ECM degradation potentiates the antitumor activity of CAR-T cells in solid tumors","volume":"21","author":"Zheng","year":"2024","journal-title":"Cell Mol. Immunol."},{"issue":"2","key":"10.1016\/j.molimm.2026.02.011_bib143","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ymthe.2024.12.014","article-title":"Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-beta signal","volume":"33","author":"Zheng","year":"2025","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.011_bib144","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/0008-5472.CAN-23-1038","article-title":"hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors","volume":"84","author":"Zhu","year":"2024","journal-title":"Cancer Res"}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589026000416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589026000416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:53:01Z","timestamp":1777492381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589026000416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":144,"alternative-id":["S0161589026000416"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2026.02.011","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating the frontier of CAR-T cell resistance: From underlying mechanisms to innovative therapeutic solutions","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2026.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}